Location History:
- Herent, BE (2012)
- Leuven, BE (2010 - 2013)
Company Filing History:
3 out of 225 
2 out of 84 
1 out of 238 
Years Active: 2010-2013
Title: Jan Cools: Innovator in Oncology
Introduction
Jan Cools is a prominent inventor based in Leuven, Belgium. He has made significant contributions to the field of oncology, particularly in the diagnosis and treatment of T-cell acute lymphoblastic leukemia. With a total of 3 patents to his name, Cools continues to push the boundaries of biotechnological innovation.
Latest Patents
Cools' latest patents include groundbreaking inventions that address critical challenges in cancer treatment. One of his notable patents is related to an episomal fusion gene. This invention pertains to an episomal structure that expresses a functional oncogene, specifically a NUP214-ABL1 fusion product. This fusion gene is crucial in the development of T-cell acute lymphoblastic leukemia and includes methods for detecting the fusion and preventing its oncogenic activity. Another significant patent focuses on the diagnosis and treatment of T-cell acute lymphoblastic leukemia. This invention outlines methods to diagnose the disease by determining the presence of a duplication of the MYB gene in patient cells. Additionally, it introduces inhibitors that can neutralize the biological activity of MYB and NOTCH1, offering new avenues for treatment.
Career Highlights
Throughout his career, Jan Cools has worked with esteemed organizations such as Vib Vzw and K.U. Leuven Research & Development. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to significant advancements in cancer research.
Collaborations
Cools has collaborated with notable colleagues, including Peter Marynen and Anne Hagemeijer. These partnerships have fostered a collaborative environment that enhances the potential for innovative breakthroughs in oncology.
Conclusion
Jan Cools is a distinguished inventor whose work in oncology has the potential to transform the diagnosis and treatment of T-cell acute lymphoblastic leukemia. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.